Zepbound vs Trulicity: Cost and Access Head-to-Head

How Zepbound and Trulicity Differ at the Molecular Level

Zepbound and Trulicity are manufactured by Eli Lilly, but they act on different receptor targets. Trulicity (dulaglutide) is a selective GLP-1 receptor agonist that mimics the incretin hormone GLP-1, slowing gastric emptying, increasing insulin secretion, and suppressing glucagon in a glucose-dependent manner. It received FDA approval in 2014 for type 2 diabetes 1.

Zepbound (tirzepatide) activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual-agonism mechanism appears to amplify weight loss and glycemic control beyond what single-incretin agents achieve. The FDA approved tirzepatide as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023 2. Although the same molecule, Zepbound and Mounjaro carry separate brand names, separate NDC codes, and separate formulary placements. This distinction matters for cost and coverage.

The pharmacokinetic profiles are similar in injection frequency. Both drugs are given as once-weekly subcutaneous injections using single-dose autoinjectors. Trulicity comes in 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg pens. Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses 3.

Efficacy: Weight Loss and Glycemic Outcomes Compared

Tirzepatide produces substantially more weight loss than dulaglutide in their respective clinical programs, though no large randomized head-to-head trial between Zepbound and Trulicity has been published. Clinicians and patients must compare across trials with the understanding that study populations differed.

In SURMOUNT-1 (N=2,539), participants without diabetes receiving tirzepatide 15 mg lost a mean 20.9% of body weight at 72 weeks compared with 3.1% in the placebo group 4. The 10 mg dose achieved 19.5% weight loss, and the 5 mg dose reached 15.0%. These results remain among the largest weight reductions documented for any approved anti-obesity medication.

Trulicity's weight-loss data come primarily from the AWARD trial program, which enrolled patients with type 2 diabetes rather than obesity alone. In AWARD-1, dulaglutide 1.5 mg produced approximately 3.0 kg weight loss at 52 weeks 5. Weight loss was a secondary endpoint, not the primary objective.

Where Trulicity distinguishes itself is cardiovascular outcome data. The REWIND trial (N=9,901) demonstrated a 12% relative risk reduction in major adverse cardiovascular events (MACE) among adults with type 2 diabetes over a median 5.4-year follow-up, with a hazard ratio of 0.88 (95% CI, 0.79, 0.99) 6. The American Diabetes Association's Standards of Care cite this evidence when recommending GLP-1 RAs for patients with established or high-risk atherosclerotic cardiovascular disease 7.

Zepbound does not yet have a completed cardiovascular outcomes trial for the obesity indication. Tirzepatide's CVOT, SURPASS-CVOT, is evaluating the Mounjaro (diabetes) formulation, and results are expected in late 2026 or 2027.

List Price Comparison

Both drugs carry similar wholesale acquisition costs despite targeting different patient populations. Zepbound's list price is approximately $1,059.87 per month for all dose strengths. Trulicity lists at roughly $1,067.52 per month 8. The near-identical sticker prices reflect Eli Lilly's pricing strategy across its incretin portfolio.

These list prices rarely represent what patients actually pay. The real cost depends on insurance coverage, formulary tier placement, and eligibility for savings programs. A commercially insured patient may pay as little as $25 per month with an active manufacturer coupon, or more than $1,000 per month if the drug falls on a non-preferred tier or is excluded entirely.

Lilly's Zepbound savings card reduces the cost to $25/month for eligible commercially insured patients whose plans cover the drug. For patients without insurance coverage for Zepbound, Lilly has offered the LillyDirect program, which provided single-dose vials at $399, $549/month depending on dose, though program terms change frequently and should be verified at the time of prescribing.

Trulicity savings cards similarly reduce copays to $25/month for commercially insured patients. Because Trulicity has been on the market since 2014, it has more established formulary placement and broader prior authorization pathways. Some Medicare Part D plans cover Trulicity as a preferred brand for type 2 diabetes, while Zepbound (approved only for obesity) is typically excluded from Medicare Part D, which does not cover anti-obesity medications under current statute.

Insurance Coverage and Formulary Access

Formulary placement creates the single largest cost difference between these two drugs for most patients. Trulicity sits on the majority of commercial formularies as a preferred or non-preferred brand-name GLP-1 RA for type 2 diabetes. An IQVIA analysis from 2024 estimated that dulaglutide maintained commercial formulary coverage exceeding 85% among large employer plans.

Zepbound faces a more restrictive coverage environment. Anti-obesity medications have historically been excluded from many employer plans, and Medicare Part D is statutorily prohibited from covering drugs prescribed solely for weight loss. The Treat and Reduce Obesity Act has been reintroduced in multiple congressional sessions but has not passed as of May 2026.

For patients with type 2 diabetes who also want weight loss, prescribers sometimes choose Mounjaro (tirzepatide's diabetes-labeled brand) instead of Zepbound to access diabetes formulary coverage. This approach is clinically reasonable because the molecule is identical, but it requires that the patient have a documented type 2 diabetes diagnosis.

Prior authorization requirements differ as well. Trulicity prior authorizations in the diabetes space are generally straightforward: a confirmed A1C above target and documentation of metformin use (or intolerance) typically satisfy payer criteria. Zepbound prior authorizations for obesity often demand BMI documentation, evidence of failed lifestyle interventions, and sometimes documentation of obesity-related comorbidities such as hypertension, dyslipidemia, or obstructive sleep apnea 9.

According to Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, "The biggest barrier to GLP-1 therapy for obesity is not clinical evidence. It is insurance coverage. Patients who would benefit most are often the ones least able to afford out-of-pocket costs."

Who Is a Better Candidate for Each Drug?

Selecting between Zepbound and Trulicity depends on the primary treatment goal, insurance status, and cardiovascular risk profile.

Trulicity is the appropriate first consideration for patients with type 2 diabetes who need glycemic control, particularly those with established cardiovascular disease or multiple cardiovascular risk factors. REWIND's 12% MACE reduction over 5.4 years provides an evidence base that Zepbound currently lacks 6. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends GLP-1 RAs with demonstrated cardiovascular benefit for patients with concurrent T2D and ASCVD 10.

Zepbound is the stronger option for patients whose primary goal is weight loss, especially those without type 2 diabetes. The 20.9% mean weight loss in SURMOUNT-1 at the 15 mg dose surpasses anything documented for dulaglutide in any trial population 4. For patients with a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity), Zepbound's label permits prescribing without a diabetes diagnosis.

Some patients fall between these categories. A patient with type 2 diabetes, a BMI of 35, and no established cardiovascular disease might benefit from tirzepatide's dual mechanism for both glucose and weight. In this scenario, prescribing Mounjaro (the diabetes-labeled brand) rather than Zepbound typically offers better formulary access while delivering the same molecule.

Switching Between Zepbound and Trulicity

Patients may need to switch between these agents for reasons of cost, coverage changes, or clinical response. No published clinical trial has studied a direct switch from tirzepatide to dulaglutide or vice versa.

When switching from Trulicity to Zepbound, prescribers typically start tirzepatide at the 2.5 mg dose regardless of the patient's prior dulaglutide dose, then titrate upward every four weeks per the Zepbound label. Gastrointestinal side effects (nausea, vomiting, diarrhea) may still occur during titration even in patients who tolerated dulaglutide without problems, because the GIP receptor agonism introduces a pharmacologic component the patient has not been exposed to previously.

Switching from Zepbound to Trulicity involves a step down in expected weight-loss efficacy. This transition most often happens when insurance coverage changes or cost becomes prohibitive. In these cases, starting at dulaglutide 0.75 mg for four weeks and titrating to 1.5 mg or higher helps manage GI tolerability, though most patients who tolerated tirzepatide will tolerate dulaglutide without difficulty.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has noted: "Transitioning between GLP-1 agents requires resetting expectations with the patient, particularly around weight trajectory. The pharmacology differs enough that a smooth clinical handoff does not mean a smooth weight-loss trajectory."

Side-Effect Profiles Compared

Both drugs share the class-wide GLP-1 gastrointestinal side-effect profile. Nausea, diarrhea, vomiting, constipation, and decreased appetite are the most commonly reported adverse events for both Zepbound and Trulicity.

In SURMOUNT-1, nausea occurred in 24.6% of participants on tirzepatide 5 mg, 26.6% on 10 mg, and 23.6% on 15 mg, compared with 9.5% on placebo. Diarrhea rates ranged from 18.7% to 21.1% across active doses 4. Most GI events were mild to moderate and occurred during dose escalation.

In Trulicity's clinical program, nausea was reported in approximately 12 to 21% of participants depending on dose, with diarrhea in 8 to 12% 5. GI tolerability tends to be somewhat better with dulaglutide than tirzepatide, likely because of the single-receptor mechanism and lower potency of appetite suppression.

Both drugs carry labeled warnings for thyroid C-cell tumors (based on rodent studies), pancreatitis, and gallbladder disease. Neither drug should be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 11.

What Happens When Trulicity Goes Generic?

Dulaglutide's primary U.S. patents are expected to expire in the late 2020s, though biologic exclusivity and patent litigation could extend Lilly's market protection. Because dulaglutide is a large-molecule biologic rather than a small-molecule chemical drug, generic entry would take the form of biosimilars rather than traditional generics. Biosimilar development requires abbreviated biologic license applications (aBLAs) and typically takes three to five years from development initiation to FDA approval.

If and when biosimilar dulaglutide reaches the market, it could reduce costs by 15 to 40% based on precedent from biosimilar adalimumab and biosimilar insulin pricing patterns 12. Tirzepatide (Zepbound/Mounjaro) patents extend further, and no biosimilar tirzepatide application is expected before the early 2030s.

For patients choosing between these drugs on the basis of long-term cost, the timeline for biosimilar availability may influence the calculus. A patient stabilized on dulaglutide could see out-of-pocket costs decline within the next several years, while a patient on tirzepatide faces a longer runway of branded pricing.

Making the Decision: A Clinical Checklist

Before prescribing, clinicians should verify five things. First, confirm the primary treatment goal: glycemic control with cardiovascular protection favors Trulicity; maximal weight loss favors Zepbound. Second, check the patient's insurance formulary status for both drugs, because coverage rules change quarterly. Third, assess cardiovascular risk using established tools like the ASCVD Pooled Cohort Equations. Fourth, review contraindications including personal/family MTC history and prior pancreatitis. Fifth, discuss realistic weight-loss expectations: 15 to 21% with tirzepatide 10 to 15 mg versus 2 to 4% with dulaglutide in non-diabetes populations.

Patients who have type 2 diabetes and obesity should be informed that Mounjaro (same molecule as Zepbound) may provide a more favorable coverage pathway while delivering identical pharmacologic effects. This prescribing nuance can save patients hundreds of dollars monthly without compromising clinical outcomes.